DREADD: A Chemogenetic GPCR Signaling Platform

Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hu, Roth, Bryan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Trends and Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4368861/
https://www.ncbi.nlm.nih.gov/pubmed/25522378
http://dx.doi.org/10.1093/ijnp/pyu007
Descripción
Sumario:Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.

Ejemplares similares